11505 RESULTS
COMMENT A surrogate marker for clinical outcomes in Alzheimer’s therapeutics has long been regarded as the Holy Grail in the field. It could definitely make new drug development much easier and faster. I agree with the authors of this position paper that, based o
COMMENT I was the director of FDA’s Division of Pharmacometrics before I left FDA in 2021. In July this year, I watched the presentation by Dr. Kevin Krudys, Associate Director, Office of Neuroscience, CDER, FDA, titled "Recent Examples of Reasonably Likely
COMMENT This publication presents a comprehensive genome-wide association study on brain and CSF metabolite levels, and reveals significant metabolic changes associated with various diseases, including Alzheimer’s. The authors have also developed a webserver that
COMMENT We are grateful for the numerous comments to our 12-author Perspective that have been posted on
COMMENT This was an ambitious study using single-nucleus RNA-Seq to characterize astrocyte heterogeneity across five brain regions in 32 donors who spanned the spectrum of Alzheimer’s disease neuropathology. The authors’ analysis of normal brains revealed astrocy
COMMENT The authors present a wonderful study that investigated, for the first time at this scale, genome-wide associations studies (GWAS) with various curated neuropathological traits. The findings are very relevant, strengthening insights into how known Alzheim
COMMENT With great respect to the authors and others in the field, I urge the field to reject the nomenclature of "brain aging," or "biological aging," as distinct from "age." We are all, including the authors of this paper, trying h
COMMENT This gene-to-molecule research is crucial for discovery in Alzheimer’s disease, offering fresh perspectives on how genetic risk factors, such as APOE, influence metabolism and perhaps disease progression. The association between APOE and glycerophospholip
COMMENT This paper by Liu and colleagues presents a novel and interesting study of protein associations with the brain age gap (BAG). The BAG approach aims to characterize biological aging of the brain based on neuroimaging features, and it has recently become qu
COMMENT I think it makes sense to concentrate on biomarker endpoints, but that doesn’t necessarily imply ignoring cognitive endpoints perpetually. Ultimately, that’s where the rubber meets the road! A broader point is that the Aβ immunotherapies are a relatively
COMMENT Let me add the perspective of a clinical trial participant. I entered a study of a mAb drug not knowing that having an APOE4 gene and a brain full of amyloid plaque would put me at higher risk for ARIA. I thought, being relatively young (65) and healthy,
COMMENT This is an extremely important discussion. I am homozygous for ApoE4, asymptomatic, a 15-year research participant in a longitudinal biomarker study, a research and AD advocate, and author of an award-winning book published by Harper-Collins of knowing my
COMMENT Aging is associated with many ailments such as cardiovascular, cancer, and neurodegenerative diseases. In this article, the authors focus on the aging brain, specifically, and how the difference between biologic aging and chronologic aging of the brain, d
COMMENT This interesting study provides valuable insights into plasma proteomic changes associated with the brain age gap (BAG), highlighting brevican and GDF-15 as markers of brain aging physiology manifesting in multimodal structural brain imaging. As described
COMMENT This new study by Liu et al. provides a clear and compelling example of how plasma proteomics can be leveraged to identify novel targets for brain disorders. Using U.K. Biobank data from nearly 11,000 individuals, the authors developed a multimodal brain-
